Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).
about
Lymphoma: immune evasion strategiesT-cell lymphomas, a challenging disease: types, treatments, and future.FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma.From empiric to mechanism-based therapy for peripheral T cell lymphoma.X. Challenges and future directions in peripheral T-cell lymphoma.The role of alisertib in treatment of peripheral T-cell lymphomas.Targets, Toxins, and T Cells--a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas.T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma.Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma.
P2860
Q28080705-D0BDB85C-42A8-4A52-80D2-D3E45214B205Q30244553-7F6A7A84-0FDB-44D0-BE23-7B5205EACEEAQ33416596-6437B79B-2A88-4E7D-BB1D-C0ADC90EC00AQ33428066-CC97CE7E-EF94-4B1A-8C66-DF5BEC160537Q33429898-BB5216D8-407D-48F3-9747-2E2CC5FC7CCBQ33702181-50B7F8E4-048B-4A38-9FCD-1E92657FDEBBQ37501114-C32F7408-2868-40BE-97AB-A3947DC214BFQ38186617-1EDBF6E4-C2FE-47E2-A81F-1B4BD6373895Q38524000-5051D127-7B3F-4A49-8973-F038F5BF650DQ38581916-03DBA9F8-3B14-4050-AB34-99ECB82F57F5Q38598544-3A71DF22-8C2F-4873-9C3C-DD2889EEEE62Q39063866-75651DC4-404B-41C7-B045-B5EE176B1010Q39978774-936D306C-2B78-4843-A98A-FA2E774D077BQ47097471-FFC5CCA8-D529-482F-8D56-CE36CDC75830
P2860
Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Bevacizumab and cyclosphospham ...... Oncology Group study (E2404).
@ast
Bevacizumab and cyclosphospham ...... Oncology Group study (E2404).
@en
type
label
Bevacizumab and cyclosphospham ...... Oncology Group study (E2404).
@ast
Bevacizumab and cyclosphospham ...... Oncology Group study (E2404).
@en
prefLabel
Bevacizumab and cyclosphospham ...... Oncology Group study (E2404).
@ast
Bevacizumab and cyclosphospham ...... Oncology Group study (E2404).
@en
P2093
P2860
P1433
P1476
Bevacizumab and cyclosphospham ...... Oncology Group study (E2404).
@en
P2093
Brad S Kahl
Fangxin Hong
Kristen Ganjoo
Lode J Swinnen
Ranjana H Advani
Sandra J Horning
Thomas M Habermann
Yasodha Natkunam
P2860
P304
P356
10.3109/10428194.2013.816700
P577
2013-07-29T00:00:00Z